Integrating Biology, Advancing Oncology Care: Siemens Leads the Way at ASTRO 2005; Siemens Exhibit and Presentations Put Oncology Workflow Solutions, Proven Outcomes in the Spotlight.

DENVER -- Siemens Medical Solutions demonstrates its commitment to radiation oncology at the American Society of Therapeutic Radiology (ASTRO) meeting, held October 16 to 19 in Denver. Building upon last year's successful presence at ASTRO, the company is highlighting its Oncology Workflow Solutions and Proven Outcomes, which support the continuum of oncology care. In addition, visitors to Siemens' booth #1617 are invited to participate in a series of live presentations exploring Siemens' multidisciplinary imaging and therapy approach to oncology.

"With more than one million new cancer diagnoses expected this year, the need for advanced therapies to treat the disease faster, safer, and more precisely is becoming increasingly important," said Ajit Singh, president, Oncology Care Systems Group, Siemens Medical Solutions. "Oncology care is progressing rapidly toward individualized treatment through the advent of molecular medicine, as we can now integrate biological information. Siemens combines cutting-edge imaging, treatment delivery, and information technologies that enable clinicians to better understand the disease and to tailor each treatment to each patient's unique needs."

The marriage of molecular imaging and oncology is enabling true Biology-Guided Radiation Therapy(TM) (BGRT), the next step in Adaptive Radiation Therapy (ART). To achieve this, Siemens is developing a range of solutions that incorporate feedback at critical points in oncology management processes.

Siemens also is actively investing in translational preclinical technologies that will accelerate the introduction of new paradigms of molecular imaging from the laboratory to the clinic. "We are prepared for the introduction of genomic and proteomic tools that will finally complete the association of the individual to the disease," added Singh. "This will in turn enable the best possible care for each patient."

At ASTRO 2005, Siemens will showcase its broad range of technologies and solutions that drive this forward-thinking, integrated approach to oncology. Innovations highlighted this year include:

--MVision(TM)*, Siemens' signature megavoltage cone beam (MVCB)* solution, which will provide CT-based, three-dimensional (3D) image acquisition. The system will be a volumetric, versatile, and cost-effective solution for efficient, automatic online targeting of the area to be treated. An ideal way to visualize soft tissue contrast inside the patient, MVCB will provide additional information for correct patient positioning prior to treatment. MVision will be available as an enhancement on the PRIMUS, ONCOR Impression and Avant-Garde linear accelerators.

--ONCOR(R) Expression*, the newest member of the ONCOR family of linear accelerators, comes standard with MVision and is designed to deliver advanced, high-quality, radiation therapy treatments in a streamlined workflow environment. The system incorporates Siemens' patented OPTIBEAM(TM) IMRT (Intensity-Modulated Radiation Therapy), an optimized technique for IMRT delivery that uses best-in-class verification to safely provide treatments with speed and accuracy.

--160 Multileaf Collimator (MLC)** leaf sequencing for efficient and improved delivery of treatment plans and high-speed optimization of beam intensities. As with the 3-D MLC and OPTIFOCUS(TM) MLC, the 160 MLC utilizes the unique integrated control system that empowers all Siemens linear accelerators and allows the MLC handling to be completely seamless.

--ARTISTE(TM)*** with In-line(TM) kilovoltage (kV) imaging is optimized for Image Guided Radiation Therapy (IGRT), Volume Guided Radiation Therapy(TM) (VGRT), Structure Guided Radiation Therapy(TM) (SGRT), and Dose Guided Radiation Therapy(TM) (DGRT). ARTISTE will offer both kV and megavoltage (MV) imaging capabilities by providing a separate radiation source and imaging panel for each energy range. The system features real-time correlation of target and delivery, as well as synchronized image and dose measurement. In addition, it provides optimized patient clearance via the most open design available.

Throughout ASTRO 2005, Siemens will host live product demonstrations and presentations showcasing these latest advances in oncology care, including sessions on dosimetry, Adaptive Targeting, and workflow and data management with COHERENCE Oncology Workspaces; the impact of particle therapy and the integration of biology in oncology; and ART, including MVCB imaging.

Considered the future of radiation oncology, ART combines the most advanced imaging and therapy technologies to allow clinicians to better visualize the changing location, shape, and size of tumors and adapt each treatment accordingly. Siemens will demonstrate its continued advances in ART solutions through its work with international collaborators at the ART Forum, held Saturday, October 15 at 11:30 a.m. in the Grand Ballroom II at the Adams Mark Hotel in Denver. The forum will bring together radiotherapy leaders from the University of California San Francisco, Fox Chase Cancer Center, and the University of Heidelberg for a presentation and panel discussion.

Siemens Medical Solutions of Siemens AG (NYSE:SI) with headquarters in Malvern, Pennsylvania and Erlangen, Germany, is one of the largest suppliers to the healthcare industry in the world. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Employing approximately 31,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.07 billion EUR, orders of 8.12 billion EUR and group profit of 1.05 billion EUR for fiscal 2004. More information can be obtained by visiting http://www.usa.siemens.com/medical-pressroom.

* Megavoltage cone beam (MVCB) is a works-in-progress (WIP), requires FDA 510(k) pre-market clearance, and is presently not for sale in the United States.

** 160 Multileaf Collimator (MLC) is a works-in-progress (WIP), requires FDA 510(k) pre-market clearance, and is presently not for sale in the United States.

*** The ARTISTE Integrated Dose-Guided Radiation Therapy (DGRT) Solution is a works-in-progress (WIP), requires FDA 510(k) pre-market clearance, and is presently not for sale in the United States.

PHOTOGRAPHY AVAILABLE UPON REQUEST